Upload
others
View
18
Download
1
Embed Size (px)
Citation preview
HYPERTHERMIA
Jackson Farrow 22 September 2010
the medical benefit of making someone hot under the collar
HYPERTHERMIA – History
► Spontaneous remission following febrile episodes?
Coley 1893 - erysipelas
Westmark 1898 - hot baths
► 1st International Congress on Hyperthermic Oncology held in Washington in 1975
Initial Results less than expected
►Failed to show evidence of beneficial effect from Hyperthermia
Subsequent review found that inadequate equipment was to blame
Preclinical findings unreliable in predicting in vivo results
► Interest resurgence due to improved technology producing promising results in new studies
HYPERTHERMIA – Mechanisms of Action
►Tumor Selective Effects? NO intrinsic difference between hyperthermia
sensitivity of normal and tumor cells
►Molecular Effects Cell membrane, Cytoskeleton Intracellular Proteins Nucleic Acids
►“Heat Shock Response” (aka Thermotolerance) Protein synthesis helps prevent against
inappropriate interaction by denatured proteins
►Cell Cycle dependent effectiveness Greatest thermosensitivity during S & M phases
HYPERTHERMIA – Mechanisms of Action
►Augmentation of Blood Flow Increased flow at moderate temperatures
► 40 - 42° C
Decreased flow above 42° C
►Solid Tumor Architecture difference in cellular organization results in a
selective advantage in targeting cancer cells chaotic growth that outstrips blood supply
► regional hypoxemia, acidosis►increased sensitivity to diminished blood flow
HYPERTHERMIA - Methods
► Local External Intraluminal/Endocavitary Interstitial
► Regional Deep Tissue Regional Perfusion Continuous Hyperthermic Peritoneal Perfusion
► Whole Body Temperature limitation of 41.8-42 C
►Thermal Conduction (surface heating) heated water suits, heated blankets, hot wax baths
►Extracorporeal Induction►Radiant/Electromagnetic Induction
von Ardenne's systemic Cancer Multistep Therapy
►WBH, hyperglycemia and hyperoxemia
HYPERTHERMIA - Thermal Radiosensitization► Radiotherapy limitations
decreased efficacy in hypoxemic environments► Oxygen presence increases free radical formation
ineffective against cells during S phase
► Adjunctive Benefit of Hyperthermia Protein denaturation complements DNA damage from Radiotherapy
► Diminished ability to repair radiation-induced damage
Increase in Radiotherapy’s capability of causing damage► Increase in blood flow allows for increase in Oxygen radical formation
S phase cell kill
► Cytotoxicity enhancement: Super Additive & Complementary Effect Enhancement influenced by proximity of administration
► Greatest benefit noted when modalities are applied synchronously
► “probably the most potent radiosensitiser known to date” van der Zee J, 2002
HYPERTHERMIA – Proven Benefits► Majority of information involves trials examining Hyperthermia’s
potential benefit in treating small, superficially located tumors Head/Neck
► Advanced nodal metastasis, Cervical Nodes Valdagni et al. showed increased complete response rates (82 vs 37%; p < .015) and an
improvement in 5-year survival rates (53 vs 0%; p = .02) in patients who received 2-6 Hyperthermia treatments in addition to full dose radiation.
Melanoma► Cutaneous, subcutaneous and peripheral lymph node metastasis
Randomized Phase III trial showed significantly higher 2 yr local-regional control rate among tumors having received adjuvant hyperthermia (46 vs 28%; p = .008) without any increase in acute or late reactions.
Breast► Local, regional recurrences
Collaborative phase III involving MRC/ESHO/PMH demonstrated examined the addition of hyperthermia to treatment of primary or recurrent breast cancers. Hyperthermia when combined with radiotherapy showed an improvement in complete response rate (59 vs 41%), lower relapse rate among complete responders at 2 yrs (17 vs 28%) and no increase in side effects.
► Chest wall metastasis, Superficial Lesions Randomized trial by RTOG involving lesions less than 3 cm showed an improvement in complete
response rates for radiation plus hyperthermia (55 vs 33%; p < .62). Upon further analysis of all superficial lesions smaller than 3 cm a statistically significant improvement in probability of local control at 12 months was demonstrated (80 vs 15%; p < .02).
► Good local control rates have been documented for superficial metastases of multiple tumors including Hodgkin’s, Merkel cell tumors, adenoid cystic carcinomas and penile metastases from prostatic cancer
HYPERTHERMIA – Head/Neck Adjunct
Study Type Complete Response Rate p value
Radiotherapy Radiotherapy
+Hyperthermia
Arcangeli et al.(1985)
Nonrandomized 42 79 < .05
Valdagni et al.(1986)
Historical Controls
35 68 .034
Valdagni et al.(1988)
Prospectively Randomized
37 82 .015
HYPERTHERMIA – Head/Neck Adjunct
Study Fields Local Control Rate (%) Time Scale
Radiotherapy Radiotherapy+
Hyperthermia
Arcangeli et al.(1984)
81 14 58 24 month
Valdagni(1994)
36 24 69 60 month
HYPERTHERMIA – Melanoma Adjunct
Study Type Complete Response Rate p value
Radiotherapy Radiotherapy+
Hyperthermia
Kim et al.(1982)
Nonrandomized, Matched Pair and Paired Lesions
42 79 < .05
Overgaard Matched Pair 20 73 < .05
Overgaard et al. Nonrandomized and Matched Pair
59 91 < .05
Gonzalez et al.(1986)
Nonrandomized Controls
50 83 –
Emani et al. (1988)
Nonrandomized Controls
24 59 .0003
HYPERTHERMIA – Melanoma Adjunct
Study Type Local Control Rate (%) Time Scale
Radiotherapy Radiotherapy+
Hyperthermia
Gonzalez et al.(1986)
24 17 83 < 36 mo
Overgaard(1987)
67 56 86 18 months
HYPERTHERMIA - Breast Adjunct
Study Type Complete Response Rate p value
Radiotherapy Radiotherapy+
Hyperthermia
Steves et al.(1986)
Matched Pair 31 45 < .05
Perez et al.(1989)
Randomized 33 55 .062
Van ser zee et al. (1988)
Nonrandomized Controls
27 82 –
RTOG Randomized 33% 55% < .62
HYPERTHERMIA - Breast AdjunctStudy Fields Local Control Rate (%) Time
ScaleRadiotherapy Radiotherapy
+Hyperthermia
RTOG 15 80 12 months
Perez et al.(1986)
70 31 61 6 months
Lindholm et al.(1987)
34 30 53 12 months
cont’d 34 30 45 24 months
TUMOR TREATMENT PATIENTS END POINT EFFECT w/ HT EFFECT w/o
Lymph nodes of Head/Neck Tumors
RT 41
CR rate 83% 41%
5-year local control 69% 24%
5-year survival 53% 0%
Melanoma RT 70
CR rate 62% 35%
2-year local control 46% 28%
Breast RT 306 CR rate 59% 41%
Glioblastoma multiforme Surgery, RT 68Median survival 85 weeks 76 weeks
2-year survival 31% 15%
Bladder, Cervix, Rectum RT 298CR rate 55% 39%
3-year survival 30% 24%
BladderRT, surgery 102 3-year survival 94% 67%
CT 52 pCR 66% 22%
CervixRT 40 CR 85% 50%
RT 64 CR 55% 31%
Various RT 92 Response 82% 63%
Lung CT 44 Response 68% 36%
Vulva/vagina CT 65 Response 59% 19%
Esophagus
RT, CT 66 CR 25% 6%
RT, CT, surgery 53 Palliation 70% 8%
RT 125 3-year survival 42% 24%
RectumRT, surgery 115 5-year survival 36% 7%
RT, surgery 122 pCR 23% 5%
van der Zee J. Heating the Patient: a promising approach?
Summary of randomized trials showing significantly better results following addition of Hyperthermia
HYPERTHERMIA - Thermal
Chemosensitization
► Adjunctive Benefit of Hyperthermia Increased blood flow allows for increased Drug concentrations Drug activity enhancement with increased temperature
►Nitrosureas, Cisplatin, Bleomycin, Doxorubicin► Resistance – Overcome or Induce?
Platinum-based compounds demonstrate increased efficacy when given in temperatures > 42° C
MDR induction► heat dependant inactivation of Topoisomerase II
► Molecular Effects Changes in fluid and electrolyte balance in addition to pH
changes alter the solubility and volume distribution of the chemotherapeutic agents
► LIMITED INFORMATION Increased Preclinical Data is needed to help direct Clinical Study
HYPERTHERMIA – Limitations ►Dosing
Difficult to produce reliable uniformity
►Different tissues absorb heat at different rates, have different levels of sensitivity
Nervous tissue (central > peripheral)
►Side effects electrolyte abnormalities decreased platelet count coagulation prolongation LFTs elevation (mild liver necrosis) CPK elevation (mild muscle necrosis) Increased CO (increased pulse rate)
►risk for arrhythmia, pulmonary edema, seizures
HYPERTHERMIA - References
►Further Research Needed
Randomized, Phase III trials
► WBH vs Local/Regional
► Proven Adjunct Benefit
Hyperthermic vs Normothermic
►Improvement in Temperature Distributions
Absolute Value
Homogeneity
HYPERTHERMIA - References
1) Luk KH, Hulse RM, Phillips TL. Hyperthermia in Cancer Therapy. West J Med 132: 179-185, Mar 1980
2) van der Zee J. Heating the patient: a promising approach? Annals Onc 13: 1173-1184, 2002
3) Hildebrandt B, Wust P, Ahlers O et al. The Cellular and Molecular Basis of Hyperthermia. Critical Reviews in Oncology/Hematology 43: 33-56, 2002.
4) Kapp DS, Hahn GM, Carlson RW. Principles of Hyperthermia. Cancer Medicine 6, 2000.